All In Biotech

Drug Trial Radar · NCT05737940

A Study of AZD3427 in Participants With Heart Failure and Pulmonary Hypertension Group 2

A Phase IIb Randomised, Double-blind, Placebo-controlled, Multi-centre, Dose-ranging Study of AZD3427 in Participants With Heart Failure and Pulmonary Hypertension Due to Left Heart Disease (WHO Group 2)

Last checked: Nov 19, 2026Latest source record: Oct 27, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingRandomized with 260 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

260

Actual

Start

Apr 24, 2023

Primary completion

Jul 15, 2025

Study completion Aug 25, 2025

Sponsor

Lead sponsor
AstraZenecaAstraZeneca (AZN)
Sponsor type
Industry
Collaborators
Parexel
First posted
Feb 21, 2023

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Triple (participant, care provider, investigator)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 130 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study is intended to assess the ability of AZD3427 to reduce pulmonary vascular resistance (PVR) after 24 weeks of treatment in participants with heart failure (HF) and pulmonary hypertension (PH) Group 2

Conditions

  • Pulmonary Hypertension (World Health Organization Group 2)
  • Heart Failure

Interventions

  • AZD3427Drug

    The participants will receive AZD3427 SC injection single dose of either Dose A or Dose B or Dose C every 2 weeks for 24 weeks.

  • PlaceboDrug

    The participants will receive SC injection of placebo single dose every 2 weeks for 24 weeks.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change From Baseline in Pulmonary Vascular Resistance (PVR)Time frame: Baseline to Week 25

Locations

60 sites in 14 countries. Site status is shown where the registry gives one.

  • Research Site

    Beverly Hills, California

  • Research Site

    La Jolla, California

  • Research Site

    New Haven, Connecticut

  • Research Site

    Baltimore, Maryland

  • Research Site

    St Louis, Missouri

  • Research Site

    Omaha, Nebraska

  • Research Site

    Rock Hill, South Carolina

  • Research Site

    Linz, Austria

  • Research Site

    Vienna, Austria

  • Research Site

    Edmonton, Alberta, Canada

  • Research Site

    Vancouver, British Columbia, Canada

  • Research Site

    Halifax, Nova Scotia, Canada

  • Research Site

    London, Ontario, Canada

  • Research Site

    Ottawa, Ontario, Canada

  • Research Site

    Toronto, Ontario, Canada

  • Research Site

    Montreal, Quebec, Canada

  • Research Site

    Beijing, China

  • Research Site

    Changsha, China

  • Research Site

    Guangzhou, China

  • Research Site

    Kunming, China

  • Research Site

    Prague, Czechia

  • Research Site

    Prague, Czechia

  • Research Site

    Prague, Czechia

  • Research Site

    Aarhus, Denmark

  • Research Site

    Copenhagen, Denmark

  • Research Site

    Berlin, Germany

  • Research Site

    Cologne, Germany

  • Research Site

    Frankfurt, Germany

  • Research Site

    Jena, Germany

  • Research Site

    Brescia, Italy

  • Research Site

    Genoa, Italy

  • Research Site

    Marche, Italy

  • Research Site

    Milan, Italy

  • Research Site

    Milan, Italy

  • Research Site

    Trieste, Italy

  • Research Site

    Bunkyō City, Japan

  • Research Site

    Kasugai-shi, Japan

  • Research Site

    Kure-shi, Japan

  • Research Site

    Nagoya, Japan

  • Research Site

    Sapporo, Japan

Showing 40 of 60 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.